Interní Med. 2013; 15(2): 52-58
New guidelines for treatment of atrial fibrillation
- I. interní klinika &ndash, kardiologická, Fakultní nemocnice Olomouc
Management of nonvalvular atrial fibrillation is recommended by Guidelines for the management of Atrial Fibrillation of the Czech
Society of Cardiology (2011), 2012 focused update of the ESC Guidelines for the management of atrial fibrillation (august 2012) with
other national limitations. Vernakalant is newly available and recommended for pharmacological cardioversion of atrial fibrillation and
dronedarone rhythm-control after cardioversion of paroxysmal or persistent atrial fibrillation. Dabigatran and rivaroxaban are preffered
instead of warfarin for anticoagulant therapy in vast majority of patients with its specific limitations.
Keywords: atrial fibrillation, vernakalant, dronedarone, CHA2DS2Vasc score, dabigatran, rivaroxaban
Published: March 8, 2013 Show citation
References
- Camm AJ, Kirchhof P, Lipp GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010: 31: 2369-2429.
Go to original source... 
Go to PubMed... - Čihák R, Heinc P, Haman L, et al. Doporučení pro... Fibrilace síní. Cor Vasa 2011; 53(1): 27-52. Go to original source...
- Camm AJ, Lipp GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J, doi: 10.1093/eurheartj/ehs253. Go to original source... Go to PubMed...
- Van Gelder IC, Groenveld HF, Crijns HJ, et al. RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373. Go to original source... Go to PubMed...
- Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for the rapid conversion of the atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117: 1518-1525. Go to original source... Go to PubMed...
- Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodaron in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57: 313-321. Go to original source... Go to PubMed...
- Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678. Go to original source... Go to PubMed...
- Connolly SJ, Camm AJ, Halperin JL, for the PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365: 2268-2276. Go to original source... Go to PubMed...
- Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-2687. Go to original source... Go to PubMed...
- Lip GYH, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med 2010; 124: 111-114. Go to original source... Go to PubMed...
- Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100. Go to original source... Go to PubMed...
- Patel MR, Mahaffey KW, Garg J, and the ROCKET AF Steering Committee for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891. Go to original source... Go to PubMed...
- Granger CB, Alexander JH, et al. for the ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-992. Go to original source... Go to PubMed...
- Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983. Go to original source... Go to PubMed...
- Lip GYH, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012; 60: 738-746. Go to original source... Go to PubMed...
- Huisman MV, at al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107(5), 838-847. Go to original source... Go to PubMed...
- van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127. Go to original source... Go to PubMed...